Literature DB >> 11730085

Acute and chronic hemodynamic effects of enhanced external counterpulsation in patients with angina pectoris.

R R Arora1, M L Carlucci, A M Malone, N V Baron.   

Abstract

BACKGROUND: Enhanced external counterpulsation (EECP) is an effective noninvasive treatment for patients with angina pectoris. However, the hemodynamic effects of EECP are still unknown and have been theorized to simulate the clinical use of the intra-aortic balloon pump, enhancing cardiac output, stroke volume, and retrograde aortic diastolic flow.
METHODS: Twelve hemodynamic parameters were measured, using the BioZ System (CardioDynamics International Corporation, San Diego, Calif) after 1 hour (n=22) and after 35 hours (n=16) of EECP treatment compared with baseline. The BioZ System noninvasively measures hemodynamic parameters using the thoracic electrical bioimpedance method.
RESULTS: One hour of EECP treatment revealed a significant decrease in cardiac output, stroke volume, contractility, afterload, preload, and myocardial energy production, but systolic time ratios and thoracic fluid content were unchanged. However, after 35 hours of therapy, stroke volume (P < or = 0.05), index of contractility (P < or = 0.05), and thoracic fluid content (P < or = 0.01) were decreased.
CONCLUSIONS: The acute reduction in contractility, preload, and concurrent bradycardia may have favorable hemodynamic effects for patients with angina pectoris. Further studies are needed to elucidate the mechanism of EECP therapy and its efficacy for patients with angina pectoris.

Entities:  

Mesh:

Year:  2001        PMID: 11730085

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  2 in total

1.  What's in the works for refractory hypertension beyond drugs and diet?

Authors:  Debbie L Cohen; Raymond R Townsend
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-12-17       Impact factor: 3.738

Review 2.  The role of enhanced external counterpulsation in the treatment of angina and heart failure.

Authors:  Rohit R Arora; Ankur G Shah
Journal:  Can J Cardiol       Date:  2007-08       Impact factor: 5.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.